A labelled Vandetanib; a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor kinase activity. The activity of vandetanib plus docetaxel was
assessed in patients with previously treated non-small-cell lung cancer (NSCLC).
